Booth Bruce 4
4 · Kymera Therapeutics, Inc. · Filed Dec 12, 2025
Insider Transaction Report
Form 4
Booth Bruce
Director
Transactions
- Sale
Common Stock
2025-12-10$88.64/sh−31,459$2,788,526→ 4,141,757 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$89.25/sh−17,825$1,590,881→ 4,123,932 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$90.14/sh−10,545$950,526→ 4,113,387 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$92.41/sh−47,349$4,375,521→ 4,066,038 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$93.20/sh−85,862$8,002,338→ 3,980,176 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$88.64/sh−5,979$529,979→ 717,267 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$89.25/sh−3,391$302,647→ 713,876 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$90.14/sh−2,001$180,370→ 711,875 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$92.41/sh−9,060$837,235→ 702,815 total(indirect: See footnote) - Sale
Common Stock
2025-12-10$93.20/sh−16,338$1,522,702→ 686,477 total(indirect: See footnote) - Sale
Common Stock
2025-12-11$91.23/sh−5,125$467,554→ 3,975,051 total(indirect: See footnote) - Sale
Common Stock
2025-12-11$91.23/sh−976$89,040→ 685,501 total(indirect: See footnote) - Sale
Common Stock
2025-12-12$91.04/sh−570$51,893→ 3,974,481 total(indirect: See footnote) - Sale
Common Stock
2025-12-12$91.04/sh−108$9,832→ 685,393 total(indirect: See footnote)
Footnotes (9)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (1), (3), (4), (5), (6), (8) and (9).
- [F2]These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $89.71 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.55 inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.9969 inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.6935 inclusive.
- [F7]The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.54 inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.33 inclusive.